- Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. to Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
May 01, 2012
FOR IMMEDIATE RELEASE- Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend......
- Pfenex Inc. and DNA2.0 Collaborate on Protein Expression Technology
March 01, 2012
FOR IMMEDIATE RELEASE: Pfenex Inc. and DNA2.0 Collaborate on Protein Expression Technology Pfenex Inc. and DNA2.0 to develop an......
- Pfenex Inc. and Prozyme Establish Joint Collaboration and Supply Agreement
January 10, 2012
-FOR IMMEDIATE RELEASE- PFENEX INC. AND PROZYME ESTABLISH JOINT COLLABORATION AND SUPPLY AGREEMENT Companies announce......
- FierceBiotech Names Pfenex a 2011 Fierce 15 Biotech
September 06, 2011
FierceBiotech Names Pfenex a 2011 Fierce 15 Biotech San Diego, CA – September 6, 2011 –......
- Pfenex Inc. Announces Strategic Agreement with SAFC
June 07, 2011
San Diego, California June 7, 2011 – Pfenex Inc., an industry leader in protein expression through the Pfēnex Expression......
- Reagent Proteins, A Division of Pfenex Inc., Announces the Commercial Launch of Full Length Circumsporozoite Protein (CSP)
June 01, 2011
San Diego, CA June 1, 2011 – Reagent Proteins, a division of Pfenex Inc., announced today that it has launched its newest product - full length......
- Pfenex Inc., Through Its Reagent Proteins Business Division Announces Submission OF Biologics Master File For Recombinant CRM197 To US FDA
May 17, 2011
San Diego, CA May 17, 2011– Pfenex Inc.’s Reagent Proteins division announced today that it has submitted a Biologics Master File (BMF) to......
- Pfenex Announces Strategic Collaboration with MedImmune for the use of Pfēnex Expression Technology™
May 10, 2011
San Diego, California, May 10, 2011 – Pfenex Inc., an industry leader in protein expression through the Pfēnex Expression Technology™......
- Boehringer Ingelheim Presents Pfēnex Expression Technology Case Study on Antibody Fragment Expression at 7th Annual PEGS Summit
May 05, 2011
Boston, MA May 5, 2011– Pfenex Inc., announced today that Dr. George Klima, Head Process Science Microbial at Boehringer Ingelheim will......
- Pfenex Inc., Through Its Reagent Proteins Business Division, Establishes Limited-Purpose CRADA With the Naval Medical Research Center and HJF
February 23, 2011
San Diego, CA February 23, 2011 – Pfenex Inc. announced today that it has entered into a Limited-Purpose Cooperative Research and Development......
- Pfenex Inc. and Boehringer Ingelheim Announce Non-Exclusive Strategic Agreement for the use of Pfenex Expression Technology™
February 15, 2011
San Diego, California, and Ingelheim, Germany, 15 February 2011 – Pfenex Inc., an industry leader in protein expression through the Pfēnex......
- Pfenex Inc. awarded sub-contract by Science Applications International Corporation (SAIC) to help develop a scalable production process based on Pfenex Expression Technology™ for a key Malaria antigen
January 26, 2011
San Diego, CA, January 26, 2011 – Pfenex Inc. today announced that Science Applications International Corporation (SAIC) has awarded Pfenex a......
- Reagent Proteins to Make Conference Exhibiting Debut and Dr. Diane Retallack to Speak at 10th Annual PepTalk Conference
January 07, 2011
San Diego, CA (January 7, 2011) – Reagent Proteins, a new division of Pfenex Inc., will be making its conference exhibiting debut at the 10th......
- Pfenex Inc., Through Its Reagent Proteins Business Division, Establishes Clinical Supply Agreement With Henry M. Jackson Foundation for the Advancement of Military Medicince
November 30, 2010
San Diego, CA (November 30, 2010) – Pfenex Inc. announced today that it has entered into a clinical supply agreement with The Henry M. Jackson......
- Pfenex Inc. Launches Reagent Proteins.com
November 02, 2010
San Diego, CA (November 2, 2010) – Pfenex Inc. today announced the launch of a new business division, Reagent Proteins. Reagent Proteins will......
- Pfenex Establishes Reagent Protein Distribution Agreement with Cedarlane Corporation
August 24, 2010
San Diego, CA (August 24, 2010) – Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement.......
- Pfenex Inc Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfēnex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthrax
August 03, 2010
San Diego, CA (August 3, 2010) – Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical......
